Form 4: Avalo Therapeutics Director Converts RSUs to Common Stock
Insider Transaction Report
Avalo Therapeutics director Aaron Kantoff converted 3,166 restricted stock units into common stock as part of a pre-scheduled vesting event.
Summary
- Director Aaron Kantoff acquired 3,166 shares of Avalo Therapeutics, Inc. common stock on March 28, 2026.
- This acquisition resulted from the conversion of 3,166 restricted stock units (RSUs) on a one-for-one basis.
- Following this transaction, Kantoff directly beneficially owns 6,333 shares of common stock.
- The transaction is part of a pre-scheduled vesting plan from an RSU grant of 9,500 units on August 13, 2024.
- After this conversion, 3,167 restricted stock units remain beneficially owned by the director, scheduled to vest on March 28, 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, reflecting a standard compensation mechanism for a director. It neither signals strong positive nor negative operational developments.
Positives
- The conversion of restricted stock units into common stock demonstrates continued equity ownership by a director, aligning their interests with shareholders.
Future Outlook
The remaining 3,167 restricted stock units are scheduled to vest on March 28, 2027, subject to the reporting person's continued service.
Industry Context
StockSavvy.ai notes that routine insider transactions, such as the vesting and conversion of restricted stock units, are common in the biotechnology and pharmaceutical sectors. These events typically reflect pre-established compensation plans and are generally not indicative of new strategic shifts or immediate operational performance changes, unlike open market purchases or sales.
Related Party Transactions
- The transaction involves the vesting and conversion of restricted stock units granted to a director, which is a form of related party compensation.
Stakeholder Impact
- Shareholders: The transaction increases the director's direct ownership, potentially aligning interests further.
- Employees: The transaction is part of a standard equity compensation structure, which can be a positive for employee retention and motivation.
Next Steps
- The final tranche of 3,167 restricted stock units is scheduled to vest on March 28, 2027.
Key Dates
| Date | Description |
|---|---|
| 08/13/2024 | Date Aaron Kantoff was granted 9,500 restricted stock units. |
| 03/28/2025 | First vesting date for 1/3 of the restricted stock units. |
| 03/28/2026 | Second vesting date for 1/3 of the restricted stock units and the transaction date for this filing. |
| 03/31/2026 | Signature date of the filing by Christopher Sullivan, Attorney-in-Fact. |
| 03/28/2027 | Third and final vesting date for 1/3 of the restricted stock units. |
Keywords
Avalo Therapeutics, AVTX, Form 4, Insider Trading, Restricted Stock Units, RSU Conversion, Director Stock Ownership, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.